About this Clinical Study
Why is this study being conducted?
The study is being conducted to determine if an investigational drug may improve the symptoms of schizophrenia that are not managed by current treatments. These symptoms may appear as a lack of motivation or emotion, or challenges with memory and thought processing.
Who may be able to participate?
This clinical study is for people who are:
What does study participation include?
Participation will last a little more than six months. During this time, participants will visit the study site for eight visits. In addition, the study staff will call them twice to see how they are feeling.
Participants will be assigned to receive either the investigational drug or placebo. Both are in the form of a pill.
- An investigational drug is a drug that is being studied and is not yet approved by the U.S. Food and Drug Administration for use outside of a research setting in the United States or elsewhere.
- A placebo looks like the investigational drug, but it does not contain active medication.
Whether a participant receives the investigational drug or placebo will be determined by chance (like flipping a coin).
Participants will have a:
- 50 percent chance of receiving the investigational drug, and a
- 50 percent chance of receiving the placebo.
Neither participants nor the study doctor will know if the participant is receiving the investigational drug or the placebo. However, if necessary for health and safety, the study doctor can find out.
- All study participants will remain on their current medication for schizophrenia during the clinical study.
- Health insurance is not required to participate, and compensation may be available.
If you are eligible and choose to participate, you will receive the following, at no cost:
- access to study-related care and monitoring of your condition by the study doctor, and
- the study drug (meaning, either the investigational drug or placebo).